



**POST-TEST & EVALUATION**

**February 2008 Edition - ACPE Program # 064-999-07-257-L01-P**

**Please Complete the Post-Test and Evaluation and Mail/Fax to:**

**THE UNIVERSITY OF TENNESSEE**

**Health Science Center**

**College of Pharmacy**

213 Conference Center

600 Henley Street

Knoxville, TN 37996

Tel: (865) 974-6605

Fax: (865) 974-2987

A statement of CE credit will be mailed within 4 weeks of successful completion and evaluation of the program.

Name \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_ Zip: \_\_\_\_\_

Phone Number: \_\_\_\_\_

License Number: \_\_\_\_\_

## POST-TEST

### Post-Test Question 1

Which ONE of the following statements MOST ACCURATELY describes the primary factors that determine the potency of topical corticosteroids in clinical practice?

#### Answer Choices for Question 1

- A. The ability of the drug molecule to activate steroid receptors.
- B. The ability of the applied formulation to deliver the steroid through the stratum corneum.
- C. The patient's propensity to apply the product.
- D. All the above statements are accurate.
- E. None of the above statements are accurate.

### Post-Test Question 2

"Ointment vehicles are superior to other psoriasis treatment vehicles because occlusion is necessary to deliver high potency topical corticosteroids." This statement is:

#### Answer Choices for Question 2

- A. True
- B. False

### Post-Test Question 3

"Patients who have failed treatment when prescribed topical calcipotriene plus a Class I topical corticosteroid should not be treated with the combination product topical betamethasone dipropionate/calcipotriene because this product only contains a Class II topical corticosteroid and will therefore be ineffective." This statement is:

### **Answer Choices for Question 3**

- A. True
- B. False

### **Post-Test Question 4**

“Psoriasis is very bothersome to patients, so invariably they are good about using their medications.” This statement is:

### **Answer Choices for Question 4**

- A. True
- B. False

### **Post-Test Question 5**

Regarding twice daily use of topical clobetasol propionate spray: as found in the Jarrett study, approximately what percentage of patients achieved clear or almost clear status at 4 weeks?

### **Answer Choices for Question 5**

- A. 20%
- B. 40%
- C. 60%
- D. 80%
- E. 100%

### **Post-Test Question 6**

“When used correctly, systemic psoriasis treatments are far more potent than are topical psoriasis treatments.” This statement is:

### **Answer Choices for Question 6**

- A. True
- B. False

## **EVALUATION**

### **Evaluation Question 1**

This program met my overall objectives.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 2**

This program enables discussion with colleagues the role of poor adherence to topical therapy on psoriasis treatment outcomes.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 3**

This program enables describing to colleagues and patients the impact of novel vehicles and combination topical medications on patient's preferences for psoriasis treatments.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 4**

This program enables discussion with colleagues and patients techniques to help improve outcomes of topical psoriasis treatment.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 5**

What is your overall opinion of this program as it applies to your clinical practice?

- A. Very useful
- B. Somewhat useful
- C. Neutral
- D. Not very useful
- E. Not at all useful

**Evaluation Question 6**

In what way(s) can this program be improved?

---

---

---

**Evaluation Question 7**

CME activities must be "free of commercial bias for or against any product." In this regard, did you perceive any commercial influence in this web-based presentation?

A. Yes (please explain)

---

---

---

B. No

**Evaluation Question 8**

Did the author(s) disclose discussion of off-label drugs and/or devices?

A. Yes

B. No (please explain)

---

---

C. N/A - There was no discussion of off-label drugs and/or devices

**Evaluation Question 9**

Would you like to receive information on other CME activities?

A. Yes - my email is:

---

B. No, thanks

**Evaluation Question 10**

Enter the number of hours it took you to complete this course (e.g., 0.5, 1.25, etc.):

---